Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 12/20 | 0.55 |
| ▸ | NTRK2 | Q16620 | 12/20 | 0.55 |
| ▸ | IGF1R | P08069 | 4/20 | 0.55 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.55 |
| ▸ | NTRK3 | Q16288 | 9/20 | 0.44 |
| ▸ | EPAS1 | Q99814 | 4/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | BCAT2 | O15382 | 2/20 | 0.37 |
| ▸ | BCAT1 | P54687 | 2/20 | 0.37 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ponazuril SCHEMBL29625926 | 1.00 | NTRK1 (0.55) | NTRK1NTRK2IGF1RFGFR1NTRK3 | |
| SCHEMBL10527532 | 0.89 | NTRK1 (0.55) | NTRK1NTRK2IGF1RFGFR1NTRK3 | |
| SCHEMBL10528041 | 0.89 | EPAS1 (0.44) | NTRK1NTRK2IGF1RFGFR1NTRK3 | |
| SCHEMBL11475552 | 0.89 | NTRK1 (0.44) | NTRK1NTRK2IGF1RFGFR1NTRK3 | |
| SCHEMBL20306614 | 0.89 | NTRK1 (0.72) | NTRK1NTRK2IGF1RFGFR1NTRK3 | |
| SCHEMBL11474624 | 0.89 | NTRK1 (0.56) | NTRK1NTRK2IGF1RFGFR1NTRK3 | |
| SCHEMBL10525700 | 0.88 | NTRK1 (0.39) | NTRK1NTRK2IGF1RFGFR1NTRK3 | |
| SCHEMBL13780151 | 0.87 | NTRK1 (0.60) | NTRK1NTRK2IGF1RFGFR1NTRK3 | |
| SCHEMBL10527978 | 0.87 | NTRK1 (0.49) | NTRK1NTRK2IGF1RFGFR1NTRK3 | |
| SCHEMBL11490392 | 0.85 | NTRK1 (0.41) | NTRK1NTRK2IGF1RFGFR1NTRK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1386 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4082524-B1 | TRIAZINE FORMULATIONS | CEVA SANTE ANIMALE SA (FR) | 2025-02-26 | — | — | EP | claimed |
| WO-2024138230-A1 | FORMULATION AND METHOD FOR TREATMENT OF INFECTIONS | VETERINARY PHARMACY CORPORATION (US) | 2024-06-27 | — | — | WO | claimed |
| US-11246836-B2 | Intramuscular depot of decoquinate compositions and method of prophylaxis and treatment thereof | BLUELIGHT PHARMATECH CO., LTD. (CN) | 2022-02-15 | — | — | US | claimed |
| CN-113999096-A | Method for synthesizing 6-methyl-5-octen-2-one by condensation hydrogenation | 万华化学集团股份有限公司 | 2022-02-01 | — | — | CN | claimed |
| US-20220008542-A1 | ANTI-PROTOZOAL COMPOUNDS AND USES THEREOF | UNIV AUBURN (US) | 2022-01-13 | — | — | US | claimed |
| US-11160867-B2 | Anti-protozoal compounds and uses thereof | AUBURN UNIVERSITY (US) | 2021-11-02 | — | — | US | claimed |
| CN-113209016-A | Iron dextran and palustralin suspension injection and preparation method thereof | 湖北龙翔药业科技股份有限公司 | 2021-08-06 | — | — | CN | claimed |
| CN-113197849-A | Suspension injection containing iron glucoheptonate and ponazuril and preparation method thereof | 湖北龙翔药业科技股份有限公司 | 2021-08-03 | — | — | CN | claimed |
| US-20210228613-A1 | FORMULATIONS CONTAINING TRIAZINONES AND IRON WITH A LOW AMOUNT OF FREE IRON IONS | BAYER ANIMAL HEALTH GMBH (DE) | 2021-07-29 | — | — | US | claimed |
| EP-3801540-A1 | FORMULATIONS CONTAINING TRIAZINONES AND IRON WITH A LOW AMOUNT OF FREE IRON IONS | Bayer Animal Health GmbH (DE) | 2021-04-14 | — | — | EP | claimed |
| CN-1331594-A | Triazineone compounds for treating diseases due to sarcosystis, neospora and toxoplasma | BAYER AG (US) | 2002-01-16 | — | — | CN | claimed |
| EP-1140101-A1 | TRIAZINEONE COMPOUNDS FOR TREATING DISEASES DUE TO SARCOSYSTIS, NEOSPORA AND TOXOPLASMA | Bayer Corporation (US) | 2001-10-10 | — | — | EP | claimed |
| EP-1140103-A2 | TRIAZINEONE COMPOUNDS FOR TREATING DISEASES DUE TO SARCOSYSTIS, NEOSPORA AND TOXOPLASMA | Bayer Corporation (US) | 2001-10-10 | — | — | EP | claimed |
| EP-1140102-A2 | TRIAZINEONE COMPOUNDS FOR TREATING DISEASES DUE TO SARCOSYSTIS, NEOSPORA AND TOXOPLASMA | Bayer Corporation (US) | 2001-10-10 | — | — | EP | claimed |
| WO-2001039778-A2 | TRIAZINONE COMPOUNDS FOR TREATING DISEASES RESULTING FROM INFESTATION WITH PARASITIC PROTOZOANS | BAYER AKTIENGESELLSCHAFT (DE) | 2001-06-07 | — | — | WO | claimed |
| US-6194408-B1 | PARASITICIDES | BAYER CORPORATION | 2001-02-27 | — | — | US | claimed |
| US-6150361-A | THERAPEUTICALLY TREATING A DISEASED ANIMAL SUFFERING FROM A PARASITIC NEUROLOGIC OR ABORTIGENIC DISEASE COMPRISING ADMINISTERING THE ANIMAL PONAZURIL, A TRIAZINEONE COMPOUND | BAYER CORPORATION (US) | 2000-11-21 | — | — | US | claimed |
| WO-2000037084-A1 | TRIAZINEONE COMPOUNDS FOR TREATING DISEASES DUE TO SARCOSYSTIS, NEOSPORA AND TOXOPLASMA | BAYER CORPORATION (US) | 2000-06-29 | — | — | WO | claimed |
| WO-2000037064-A2 | TRIAZINEONE COMPOUNDS FOR TREATING DISEASES DUE TO SARCOSYSTIS, NEOSPORA AND TOXOPLASMA | BAYER CORPORATION (US) | 2000-06-29 | — | — | WO | claimed |
| WO-2000037063-A2 | TRIAZINEONE COMPOUNDS FOR TREATING DISEASES DUE TO SARCOSYSTIS, NEOSPORA AND TOXOPLASMA | BAYER CORPORATION (US) | 2000-06-29 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220008542-A1 | ANTI-PROTOZOAL COMPOUNDS AND USES THEREOF | PPIP5K2, PIGS, PGLS | NTRK1 4841/4885NTRK2 4873/4885IGF1R 4879/4885 |
| US-11160867-B2 | Anti-protozoal compounds and uses thereof | PPIP5K2, PIGS, PGLS | NTRK1 4841/4885NTRK2 4873/4885IGF1R 4879/4885 |
| US-11246836-B2 | Intramuscular depot of decoquinate compositions and method of prophylaxis and treatment thereof | HMGCR, DECR1, GYS1 | NTRK1 4779/4885NTRK2 3889/4885IGF1R 2810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.